Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1877
http://purl.obolibrary.org/obo/NCIT_C1877
|
|---|---|
| Preferred Name | Cositecan |
| Definitions |
A synthetic silicon-containing agent related to camptothecin with antineoplastic properties. Cositecan stabilizes the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks and consequently triggering apoptosis. Because it is lipophilic, cositecan exhibits enhanced tissue penetration and bio-availability compared to water-soluble camptothecins.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic silicon-containing agent related to camptothecin with antineoplastic properties. Cositecan stabilizes the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks and consequently triggering apoptosis. Because it is lipophilic, cositecan exhibits enhanced tissue penetration and bio-availability compared to water-soluble camptothecins. |
|---|---|
| prefLabel | Cositecan
|
| label | Cositecan
|
| PDQ_Closed_Trial_Search_ID | 38211
|
| code | C1877
|
| Has_Target | |
| prefixIRI | NCIT:C1877
|
| in_subset |
See more
See less
|
| Display_Name | Cositecan
|
| Preferred_Name | Cositecan
|
| FDA_UNII_Code | 24R60NVC41
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C25H28N2O4Si
|
| Maps_To | Cositecan
|
| CAS_Registry | 203923-89-1
|
| NSC Number | 710270
|
| NCI_Drug_Dictionary_ID | 38211
|
| Legacy Concept Name | Karenitecin
|
| type | |
| ALT_DEFINITION | A drug being studied in the treatment of cancer. It belongs to a family of drugs called topoisomerase inhibitors. It is related to the anticancer drug camptothecin.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38211
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0935985
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |